Do you want to read an article? Please log in or register.
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial
Lancet Respir Med
Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS
doi: 10.1016/S2213-2600(26)00192-X
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
Lung Cancer
Lymphatic Invasion Acts as a 'Hidden Risk Factor': Four-Fold Increased Mortality Risk in Early-Stage (TNM Stage I, N0) Non-Small Cell Lung Cancer
J Clin Med
Özer KB, Erus S, Cesur E, Güzey Ö, Bulutay P, Tanju S, Fırat P, Dilege Ş
doi: 10.3390/jcm15124582
Lung Cancer
Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Clin Lung Cancer
Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, Hojo H, Fujisawa T, Yamashita R, Haeno H, Kanai A, Suzuki Y, Yamaguchi M, Tsuchihara K, Zenda S
doi: 10.1016/j.cllc.2025.09.013
Lung Cancer
Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review
Clin Lung Cancer
Maity AP, Kjelstrom S, Gu H, Sanborn M, Kalola A, Savior D, Ghaneie A, Dessain SK
doi: 10.1016/j.cllc.2026.08.004
Lung Cancer
Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation
Clin Lung Cancer
Suda K, Sakai K, Ito M, Oiki H, Fukuda S, Ohara S, Hamada A, Chiba M, Shimoji M, Nishio K, Tsutani Y
doi: 10.1016/j.cllc.2026.03.002
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005
COMMENTED
Lung Cancer
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Ann Oncol
Wakelee H, Spicer JD, Gao S, Liberman M, Tsuboi M, Kato T, Chen KN, Dooms C, Majem M, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Halmos B, Jones DR, Chaft JE, Reck M, Jensen E, Keller SM, Samkari A, Garassino MC
doi: 10.1016/j.annonc.2026.08.005